Key result
Intraoperative use of dexmedetomidine as an anesthetic adjuvant was associated with a 47% reduced odds of major complications and prolonged CICU length of stay after heart valve surgery.
Why the study?
The relationship between dexmedetomidine as an anesthetic adjuvant in cardiac surgery and postoperative complications and cardiac intensive care unit length of stay needed exploration.
Does intraoperative dexmedetomidine reduce major postoperative complications and prolonged CICU length of stay in adult patients undergoing heart valve surgery?
Observational (n=856)
No
Does intraoperative dexmedetomidine reduce major postoperative complications and prolonged CICU length of stay in adult patients undergoing heart valve surgery?
Intraoperative use of dexmedetomidine as an anesthetic adjunct during heart valve surgery is associated with a significantly reduced risk of major postoperative complications and prolonged CICU length of stay.
Answers are grounded in this paper and cite their sources.
Should not yet alter anesthetic practice in valve surgery; leaves open a potential benefit pending randomized confirmation.
Background: We sought to explore the relationship between dexmedetomidine as an anesthetic adjuvant in cardiac surgery and postoperative complications and length of stay (LOS) in the cardiac intensive care unit (CICU). Methods: We conducted a retrospective study of patients aged 18 years and older who underwent heart valve surgery between October 2020 and June 2022. The study endpoints were a combination of adverse outcomes, which included major postoperative complications (cardiac arrest, atrial fibrillation, myocardial injury/infarction, heart failure) and prolonged CICU LOS (defined as LOS≥90th percentile). Multivariate logistic regression analysis was performed for variables that were significant in the univariate analysis. Results: A total of 856 patients entered our study. Of these, 283(33.06%) patients experienced at least one adverse outcome and the remaining 573 were included in the prognostic control group. Multivariate logistic regression analysis revealed that age > 60years (odds ratio [OR], 1.73; 95% confidence interval [CI], 1.27–2.37; p=0.01), cardiopulmonary bypass( CPB)> 190min (OR, 1.58; 95% CI, 1.01-2.48; p = 0.04) and postoperative mechanical ventilation time > 10 h (OR, 2.03; 95% CI, 1.49-2.77; p < 0.01) were independent risk factors for major complications and prolonged CICU length of stay in patients undergoing heart valve surgery. Intraoperative use of dexmedetomidine as an anesthetic adjuvant was a protective factor for such patients (odds ratio, 0.53; 95% confidence interval, 0.37-0.78; p = 0.01). Conclusions: Age, duration of cardiopulmonary bypass, and duration of mechanical ventilation are associated with major complications and increased CICU stay after heart valve surgery. Intraoperative use of dexmedetomidine may improve such clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2023) conducted an observational in Heart valve surgery (n=856). Intraoperative dexmedetomidine vs. No intraoperative dexmedetomidine was evaluated on Combination of adverse outcomes (major postoperative complications and prolonged CICU length of stay ≥ 6 days) (OR 0.53, 95% CI 0.37-0.78, p=0.01). Intraoperative use of dexmedetomidine as an anesthetic adjuvant was associated with a 47% reduced odds of major complications and prolonged CICU length of stay after heart valve surgery.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: